| Amarilis Rosado, PHARM D | |
|
Carr 160 Km 4.4 Almirante Norte, Vega Baja, PR 00693 | |
| (787) 369-6868 | |
| Not Available |
| Full Name | Amarilis Rosado |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | Carr 160 Km 4.4 Almirante Norte, Vega Baja, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023658796 | NPI | - | NPPES |
| 5221 | Other | PR | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 5221 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Amarilis Rosado, PHARM D 421 Calle Tulane, Estancias De Tortuguero, Vega Baja, PR 00693 Ph: (787) 369-6868 | Amarilis Rosado, PHARM D Carr 160 Km 4.4 Almirante Norte, Vega Baja, PR 00693 Ph: (787) 369-6868 |
News Archive
Illumina, Inc. today announced the launch of a Cancer Analysis Service from the Illumina Genome Network (IGN) that leverages the high accuracy of Illumina technologies to provide cancer researchers with easily interpretable tumor/normal sequencing data to quickly move their research forward.
Finding the right treatment for people living with chronic intestinal inflammation, also known as inflammatory bowel disease, might soon be getting easier.
Watson Pharmaceuticals, Inc. has announced today that it has received final approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-Release Capsules USP in the 10mg, 20mg and 40mg strengths.
PatientKeeper, Inc., the leading provider of Physician Information Technology, today announced that it has closed a $13 million round of funding comprised of equity and debt.
Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.
› Verified 6 days ago
Brenda L Torres, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 37 Calle Betances, Vega Baja, PR 00693 Phone: 787-858-2280 Fax: 787-858-2280 | |
Luis Enrique Velazquez Marrero, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Calle Publica Carretera 2, Vega Baja, PR 00693 Phone: 787-855-3044 | |
Julia Evelyn Marrero, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Villas De La Playa 172, Vega Baja, PR 00693 Phone: 787-316-9761 | |
Dr. Danister Quinones, PHD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Calle Publica & Carr 2, Vega Baja, PR 00693 Phone: 787-855-3044 Fax: 787-855-3301 | |
Ramon M. Cano, BSPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: C2 Calle 2, Villa Real, Vega Baja, PR 00693 Phone: 787-858-1336 Fax: 787-858-1336 | |
Mrs. Flor Ruby Rosario, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Street 2 #13 San Vicente, Vega Baja, PR 00693 Phone: 787-608-4671 |